One of the supposed mechanisms that may lead to breast cancer (BC) is an alteration of circadian gene expression and DNA methylation. We undertook an integrated approach to identify methylation pattern of core circadian promoter regions in BC patients with regard to clinical features. We performed a quantitative methylation-specific real-time PCR analysis of a promoter methylation profile in 107 breast tumor and matched non-tumor tissues. A panel of circadian genes CLOCK, BMAL1, PERIOD (PER1, 2, 3), CRYPTOCHROME (CRY1, 2) and TIMELESS as well as their association with clinicopathological characteristics were included in the analysis. Three out of the eight analyzed genes exhibited marked hypermethylation (PER1, 2, 3), whereas CLOCK, BMAL1, CRY2 showed significantly lower promoter CpG methylation in the BC tissues when compared to the non-tumor tissues. Among variously methylated genes we found an association between the elevated methylation level of PERs promoter region and molecular subtypes, histological subtypes and tumor grading of BC. Methylation status may be associated with a gene expression level of circadian genes in BC patients. An aberrant methylation pattern in circadian genes in BC may provide information that could be used as novel biomarkers in clinics and molecular epidemiology as well as play an important role in BC etiology.
Background: Metastatic disease is still one of the most common cause of death among women suffering from breast cancer. Cancer cells, which detached from the primary tumor and mediate the metastasis process, can be found also in blood stream of early breast cancer patients. Detachment from tumor mass and intravasation of these circulating tumor cells (CTCs) might be enhanced by epithelial to mesenchymal transition (EMT), what is associated with progression of the disease. Due to relative rarity of CTCs in early breast cancer patients molecular characteristics of these cells are not well known. Since stem cell-like properties of cancer cells seems to be connected with EMT, we decided to investigate the expression of genes linked with stem cell-like properties of epithelial and mesenchymal CTCs and its impact on patients outcome.